

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Name	Won Kim
Affiliation	Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center
Country	Republic of Korea
Major Field	Integrated multi-omics approach for precision medicine in NAFLD

Educational Background

1991-1997 Bachelor's degree, Seoul National University College of Medicine
2000-2002 Master's degree, Seoul National University College of Medicine
2005-2007 Doctoral degree, Seoul National University College of Medicine

Professional Experience

2020-now Associate Professor, Seoul National University College of Medicine
2018-2019 Director of Research Committee, Korean Liver Cancer Association
2022-2023 Director of Research and Project Committee, Korean Association for the Study of Liver
2024-now Director of Publication Committee, Korean Association for the Study of Liver
2024-now Editor-in-Chief, Clinical and Molecular Hepatology (IF 8.9)
2023-now President, KASL-Alcohol-Related Problem Study Group

Main Scientific Publications

1. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. *Journal of Hepatology* (2017)
2. Activating Transcription Factor 3 Is a target molecule linking hepatic steatosis to impaired glucose homeostasis. *Journal of Hepatology* (2017)
3. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. *Journal of Hepatology* (2019)
4. Overproduction of inter--trypsin inhibitor heavy chain 1 after loss of G13 in liver exacerbates systemic insulin resistance in mice. *Science Translational Medicine* (2019)
5. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. *Nature Communication* (2020)
6. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. *Journal of Hepatology* (2021)
7. A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects with Nonalcoholic Fatty Liver Disease. *Clin. Gastroenterol. Hepatol.* (2022)
8. Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. *Gut Microbes* (2022)
9. Myosteatorsis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. *Clin. Gastroenterol. Hepatol.* (2023)
10. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. *JAMA Internal Medicine.* (2024)